Journal of Clinical Oncology
Articles in this Issue
Safety, tolerability, and efficacy of mesutoclax (ICP-248) in combination with azacitidine in patients with myeloid malignancies.
6506 Background: Venetoclax has been approved for the treatment of newly diagnosed acute myeloid leukemia (AML) in elderly...
Preliminary efficacy and safety of intratumoral long-acting cisplatin-SRGel (TumoCure) in refractory locally advanced head and neck squamous cell carcinoma: Phase Ib CLPR-001.
6051 Background: Refractory LA-HNSCC progressing despite standard therapies is associated substantial locoregional disease...
Correlation of presurgical circulating tumor DNA (ctDNA) levels with pathologic (p) stage and lymph node (LN) burden in localized colon cancer.
3048 Background: Accurate preoperative staging is vital for tailoring neoadjuvant therapy (NAT) in localized colon cancer....
Impact of artificial intelligence on inter-reader variability in breast ultrasound interpretation: An international multireader multicase study.
e12552 Background: Artificial intelligence (AI) has been developed as a promising assistive tool for improving diagnostic...
Real-world efficacy and safety outcomes of older adult patients on enfortumab vedotin for urothelial carcinoma.
e13767 Background: The treatment landscape for advanced urothelial carcinoma (aUC) has undergone a significant transformat...
Impact of prior chemotherapy (CT) on dabrafenib plus trametinib (D + T) outcomes in <i>BRAF</i> <sup>V600E</sup> –mutated metastatic non–small cell lung cancer (NSCLC): A post hoc analysis.
e20666 Background: The Phase II study (NCT01336634) evaluated the BRAF inhibitor, dabrafenib with the MEK inhibitor, trame...
Fruquintinib in combination with sintilimab and CAPEOX as first-line treatment for advanced gastric/gastroesophageal junction adenocarcinoma: A single-arm, open-label, multicenter phase Ib/II study (FUNCTION).
e16033 Background: The combination of immune checkpoint inhibitors (ICIs) and chemotherapy has become the standard first-l...
Clinical efficacy of a novel oral SERD TFX06 in prior fulvestrant-treated ER+/HER2− advanced breast cancer patients in a dose expansion study.
1062 Background: Patients with ER+/HER2- advanced breast cancer who have progressed on prior endocrine therapies, includin...
A phase 2 study of fedratinib in patients with MDS/MPN and chronic neutrophilic leukemia.
6509 Background: MDS/MPNs are complex diseases that exhibit proliferative symptoms and aggressive clinical courses. Treatm...
A phase II clinical trial of ivonescimab (VEGFxPD-1 bispecific antibody) in patients with metastatic castration-resistant prostate cancer (mCRPC).
TPS5138 Background: Patients with mCRPC achieve limited responses with single-agent immune checkpoint therapies (ICTs), du...
Longitudinal palliative care delivery in oncology in a resource-constrained setting: Experience from 1,500 patients in Albania.
e24077 Background: Early integration of palliative care is a core component of high-quality oncology care; however, access...
Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Final analysis results from the phase 3 KEYNOTE-522 study.
507 Background: KEYNOTE-522 (NCT03036488) showed statistically significant and clinically meaningful improvements in pCR,...
Immunotherapy-based total neoadjuvant therapy versus neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cancer: Interim results of a randomized phase 2 study.
e16110 Background: Long-term outcomes of neoadjuvant chemoradiotherapy (nCRT) for locally advanced esophageal squamous can...
Evolving trends in young adult (YA) gastrointestinal (GI) cancer: Philadelphia in national context.
e15706 Background: GI malignancies in YA (ages 18-39) have increased in the past several decades, with advanced stages at...
Understanding the understanding: Patient assessment of goals and treatment in oncology.
e24066 Background: Metastatic disease is typically treated with the goal to prolong life, but not cure the disease, or wha...
A study of MT-4561 in patients with various advanced solid tumors (NCT06943521).
TPS3178 Background: MT-4561 is a bromodomain-containing protein 4 (BRD4) protein degrader, which is a bi-functional molecu...
Socioeconomic and treatment-related determinants of long-term cancer survival: A population-based SEER outcomes analysis.
11186 Background: Cancer survival is shaped by tumor biology, treatment access, and socioeconomic context, yet population-...
Impact of the Taylor Cancer Research Center (TCRC) and Tempus AI TIME Partnership on clinical trial start-up and accrual.
1565 Background: TCRC is a nonprofit oncology community practice serving patients in Northwestern Ohio. TCRC's partnership...
Standardized exam-style benchmarking of large language models in breast cancer clinical decision-making.
553 Background: Large language models (LLMs) are increasingly used to support clinical reasoning in breast cancer (BC), ye...
Factors associated with time to breast cancer treatment initiation at an urban safety net center.
e13750 Background: Delays in cancer treatment initiation are associated with increased mortality and may disproportionatel...
Does neoadjuvant chemotherapy matter in endocrine-sensitive breast cancer?: Insights from a 10-year SEER cohort.
e12626 Background: In ER+/HER2– breast cancer, neoadjuvant chemotherapy (NAC) is used far less frequently than in other bi...
Real-world use of piflufolastat F 18 and imaging-associated treatment patterns in early-stage prostate cancer.
e17126 Background: Positron emission tomography (PET) imaging with piflufolastat F 18, a PSMA-targeted radiotracer for pro...
Incidence trends and factors affecting survival in thymic carcinoma: Insights from SEER data.
e20169 Background: Thymic carcinoma is a rare neoplasm, accounting for less than 0.01% of new cancer diagnoses annually. I...
Expanding cfDNA capture beyond nucleosome-sized fragments to enhance liquid biopsy performance.
e15062 Background: Liquid biopsy is a non-invasive diagnostic approach used for early cancer detection, disease monitoring...
Cancer stigma in low- and middle-income countries: A scoping review of frameworks, measurement approaches, and interventions.
1590 Background: The incidence and mortality rates of cancer are rising fastest in low- and middle-income countries (LMICs...